现代医院Issue(7)：36-37,40,3.DOI:10.3969/j.issn.1671-332X.2014.07.014
碳酸镧对维持透析患者高磷血症的疗效分析
EFFECT OF LANTHANUM CARBONATE ON HYPERPHOSPHATEMIA IN DIALYSIS PA-TIENTS
摘要
Abstract
Objective To Investigate the short-term efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia in dialysis patients.Methods The clinical data of dialysis patients ( hemodialysis or peritoneal dialysis) with hyperphosphatemia who were given with lanthanum carbonate treatment from October 2012 to October 2013 in our hospi-tal were retrospectively analyzed.Results A total of 22 cases were enrolled.Of all the 22 cases, there were 13 cases of males, 9 cases of females; 4 cases of peritoneal dialysis, and 18 cases of hemodialysis.Their average age was (54.2 ± 15.1) years, and their average dialysis age was (51.5 ±21.4) months.Before the treatment and 12 weeks after the treat-ment, serum phosphorus, corrected serum calcium, calcium-phosphorus product and iPTH were (2.94 ±0.43) vs (2.31 ± 0.39) (p=0.00), (2.23 ±0.11) vs (2.26 ±0.10) (p=0.25), (82.2 ±12.9) vs (65.3 ±11.1) (p=0.00), (1 462 ±1 053) vs 1 411 ±943) (p=0.51).The main adverse reactions were gastrointestinal reactions.The incidence of adverse effects was 36.4%.No patient quitted from this study for safety reason.Conclusion Lanthanum carbonate is a well-tolera-ted oral phosphate binder with a good short-term curative effect and light adverse reactions in treatment of hyperphosphatemia in dialysis patients.关键词
碳酸镧/高磷血症/透析/磷结合剂Key words
lanthanum carbonate/hyperphosphatemia/dialysis/phosphate binder引用本文复制引用
陈林,刘日光,陈浩雄,陈磊,傅君舟..碳酸镧对维持透析患者高磷血症的疗效分析[J].现代医院,2014,(7):36-37,40,3.基金项目
广州市科技计划项目 （）
